Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Oxis International Inc. (OXIS)

Add OXIS Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski
Search This Board: 
Last Post: 6/24/2017 10:53:59 PM - Followers: 165 - Board type: Free - Posts Today: 0


Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!


Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.



Company Website


Corporate Overview - Presentation
Fall 2015
Click the link:





OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet




Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.


Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.


Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.


Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.


Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.


Stock Information:

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OXIS News: Information Statement - All Other (definitive) (def 14c) 05/12/2017 04:03:59 PM
OXIS News: Information Statements (revised) (prer14c) 05/05/2017 05:21:15 PM
OXIS News: Quarterly Report (10-q) 04/28/2017 04:23:56 PM
OXIS News: Information Statements (revised) (prer14c) 04/24/2017 05:30:49 PM
OXIS News: Information Statements (revised) (prer14c) 04/14/2017 01:07:47 PM
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#10576   $12M D get ready for a convert avalanche lol Jmo chaostrader 06/24/17 10:53:59 PM
#10575   r/s is a cometh very soon Jmo chaostrader 06/24/17 10:52:58 PM
#10574   Sorry, not my intention to offend, time will mrcraigo 06/23/17 04:17:46 PM
#10572   Ok, sorry boss, I sadly disagree..... I feel bad mrcraigo 06/23/17 02:00:30 PM
#10568   Good job superman u really killed this stock Bishop123 06/21/17 05:41:18 PM
#10567   oh, R/S still not happened yet? chromaticity 06/14/17 02:59:14 PM
#10566 jimbosskow 06/13/17 02:44:10 PM
#10565   I don't doubt the existence of the trial. simon wagstaff 06/12/17 10:30:11 PM
#10564   The real question is how much your ownership scoot27 06/12/17 04:50:44 PM
#10563   Interestingly and coincidentally, I got to meet a Rando3 06/12/17 03:27:00 PM
#10562   mrcraigo - watch. Sadly you are wrong. Gibba 06/10/17 02:33:31 PM
#10561   I thought so. From what I can remember, CashBowski 06/09/17 03:37:14 PM
#10560   Funny, I can't find it anywhere, but this simon wagstaff 06/09/17 03:14:15 PM
#10559   Funny, I read the same thing........... mrcraigo 06/09/17 02:11:37 PM
#10558   I believe it's 100:1. I saw it buried CashBowski 06/09/17 01:47:48 PM
#10557   Ok Simon, time will tell..... let's circle back mrcraigo 06/09/17 12:42:18 PM
#10556   Both of them are good teams that earned simon wagstaff 06/09/17 12:40:36 PM
#10555   Some people took the Cavs and the others mrcraigo 06/09/17 12:16:28 PM
#10554   You have specific information on the split ratio? simon wagstaff 06/09/17 09:01:53 AM
#10553   Don't be gun shy, opportunity is right in mrcraigo 06/08/17 09:30:44 PM
#10552   100 to 1...... due diligence my friend, IMO, mrcraigo 06/08/17 09:27:08 PM
#10551   I looked mine today. It doesn't specify it. jimbosskow 06/07/17 05:27:45 PM
#10550   Trying to pay-down debt @.75 post R/S value? Gibba 06/06/17 07:54:55 PM
#10549   :) simon wagstaff 06/06/17 07:52:04 PM
#10548   I looked for the letter last night and Kuberax 06/06/17 04:12:28 PM
#10547   57 for one R/S does not sound correct Gibba 06/06/17 11:53:37 AM
#10546   20 days from the date of mailing, countdown simon wagstaff 06/05/17 06:21:25 PM
#10545   It can be anywhere from 50-1 to 300-1 simon wagstaff 06/05/17 06:13:03 PM
#10544   I got the same letter. I don't Kuberax 06/05/17 05:19:11 PM
#10543   I didn't think so.... simon wagstaff 06/05/17 02:05:26 PM
#10542   So, what is the split ratio? simon wagstaff 06/05/17 11:18:56 AM
#10541   It did. I will post Monday. Soup Stock 06/02/17 09:37:07 PM
#10540   Surely the letter stated what the split ratio was? simon wagstaff 06/02/17 03:22:26 PM
#10539   How good or bad is it? Cavs_2016 06/02/17 12:55:30 PM
#10538   Reverse split notification tried to paste a copy Soup Stock 06/02/17 12:44:44 PM
#10537   Can you go into a little bit more Cavs_2016 06/02/17 11:40:06 AM
#10535   u should have gotten a metal ! Fibanotch 06/02/17 10:22:38 AM
#10534   Got the letter in the mail this past weekend Soup Stock 06/02/17 08:13:58 AM
#10533   R/S not happen yet? hold too long? chromaticity 05/31/17 12:35:25 PM
#10532   That doesn't sound too bad considering..... simon wagstaff 05/31/17 10:40:20 AM
#10530   Of course Cheds 05/30/17 08:05:21 PM
#10529   Sir, Cheds Cavs_2016 05/30/17 06:52:19 PM
#10528   In Cheds 05/30/17 12:18:30 PM
#10527   I get it mrcraigo 05/28/17 03:56:59 PM
#10526   Thanks guys Bishop123 05/26/17 11:42:18 AM
#10525   I am certainly no expert on this. simon wagstaff 05/26/17 11:10:57 AM
#10524   jumping in for simon. simon, correct me OxisWatcher 05/26/17 11:00:28 AM
#10523   Simon I have a question I am a Bishop123 05/25/17 07:13:40 AM
#10522   Yes, but happy to be out at .19+ Gibba 05/24/17 07:44:11 PM
#10521   Perhaps ypu should read the latest filimg. I simon wagstaff 05/24/17 12:21:23 PM